Oct 05 2026 09:36 PM EST

Oct 05 2026 09:13 PM EST

Petrobras, Lumentum and Coherent Lead Gains; FICO and Alnylam Lag on Regulatory and Clinical Setbacks

Shares of three companies—Petrobras (NYSE: PBR), Lumentum (NASDAQ: LITE) and Coherent (NYSE: COHR)—advanced sharply over the past five trading days, driven by strong earnings, AI‑related demand and new supply agreements. In contrast, Fair Isaac (NASDAQ: FICO) and Alnylam (NASDAQ: ALNY) fell sharply after regulatory actions and a disappointing earnings release eroded investor confidence.

Petrobras Gains on Election Lead and Q2 Earnings

Petrobras (NYSE: PBR) opened the week with a pre‑market surge of 10.32% on October 5, 2026, and closed at $21.78, up 2.96% from the prior session. The move coincided with a surprise first‑round lead for right‑wing candidate Flávio Bolsonaro and the release of Q2 2026 results that beat expectations, prompting investors to reassess the company’s cash‑flow profile and dividend outlook.

Q2 2026 revenue rose to $33.6 billion, a 60% increase YoY, while net income jumped 120% to $10.4 billion. Adjusted EBITDA reached $20.0 billion. Operating cash flow of $12.3 billion generated free cash flow of $7.7 billion, supporting a dividend payout of R$17.4 billion (≈US$3.35 billion) and an 8 % dividend yield.

Election Lead Reduces Political Risk

Brazil’s first‑round presidential vote on October 2 produced an unexpected lead for Bolsonaro, lowering perceived governance risk for state‑controlled firms. The market interpreted the result as a potential shift toward tighter fiscal policy, which historically improves the risk profile of Petrobras’ debt and enhances the attractiveness of its dividend‑heavy payout policy.

Q2 Results Reinforce Cash‑Flow Strength

The quarter’s earnings were driven by a record‑high pre‑salt lifting cost of $4.45 per barrel and an average Brent price of $104.52, well above the 2026 breakeven level of $59 per barrel used in the company’s 2026‑2030 business plan. Gross debt stood at $70.8 billion, keeping the net‑debt‑to‑EBITDA ratio at 1.14×, comfortably below the plan’s 1.5× ceiling.

Operational Upside from New Discovery

During the same period Petrobras announced a second crude discovery at the ultra‑deepwater Morpho well in the Foz do Amazonas basin, confirming high‑quality reserves. The departure of the P‑80 FPSO for the Búzios pre‑salt field also signaled that medium‑term production growth remains on schedule, reinforcing the company’s reserve‑replacement outlook.

Macro Tailwinds Support Oil Prices

Brent crude traded around $100.21 per barrel on October 5, buoyed by ongoing Middle‑East tensions and OPEC+’s decision to keep output cuts in place. Refining margins remained elevated, with the 3‑2‑1 crack spread averaging $65.61 per barrel in August, providing additional upside to Petrobras’ integrated model.

Valuation and Investor Sentiment

At the close of the week the stock traded at roughly 4.5× forward earnings, a discount of about 60% to the broader market. Analyst consensus remains a “Buy” with an average price target of $22.51. Technical indicators showed a MACD buy signal (0.213) and an RSI of 77.2, suggesting momentum but also overbought conditions.

Risks and Uncertainties

Key risks include a potential slowdown in dividend growth—dividends have fallen 42.5 % over the past three years—and operational challenges such as integrity expenses and subsea inspections in pre‑salt fields. A reversal in the election outcome or a sharp decline in Brent prices below the 2026 breakeven level could also erode cash‑flow generation and pressure the stock.

AI‑Optics Winners: Lumentum and Coherent

Shares of Lumentum Holdings Inc. (NASDAQ: LITE) have risen nearly 14% over the past five days, propelled by record quarterly results, sustained momentum in AI-driven optical demand, and a multi‑year supply agreement with Nvidia. The move has elevated Lumentum’s market capitalization to approximately $88.7 billion, with investors interpreting the company’s recent developments as evidence of its strengthening position in critical AI and cloud infrastructure markets.

KEY FIGURES

Q4 Revenue

$1.01 billion

↑ 109.3% YoY

Non-GAAP EPS

$3.23

↑ 267% YoY

Market Cap

$88.7 billion

Q1 FY27 Guidance (EPS)

$4.05–$4.35

Lumentum’s latest results, reported August 11, 2026, showed net revenue of $1.01 billion, up 109.3% year‑over‑year, and non‑GAAP earnings per share of $3.23, beating consensus estimates by 11%. The company’s Q1 FY27 guidance projects EPS between $4.05 and $4.35, underscoring management’s confidence in continued momentum as demand for high‑speed optical components accelerates.

The central catalyst has been explosive growth in orders for AI and cloud data center optics, led by hyperscale customers shifting from copper to photonic interconnects. Lumentum’s landmark $2 billion supply agreement with Nvidia, including investment in a new U.S. fab, has provided long‑term visibility and capacity commitments, with reported production sold out through 2027.

AI Infrastructure Drives Revenue Surge

Lumentum’s Q4 results reflected sector‑leading growth, with revenue doubling year‑on‑year and gross margin expanding to 47.4% on a GAAP basis. Non‑GAAP operating margin reached 36.6%, marking a substantial improvement from prior periods.

Coherent’s Record Q4 and Nvidia Partnership

Coherent Corp (NYSE: COHR) rose 6% on September 18, 2026 after a string of operational and strategic updates reinforced expectations of continued revenue acceleration and margin expansion.

The stock’s 5‑day gain of 23.9% follows the company’s record Q4 FY 2026 results – revenue of $2.05 billion (+34% YoY) and GAAP EPS of $1.19 – and a Q1 FY 2027 outlook that projects revenue of $1.7‑$1.84 billion with non‑GAAP EPS of $1.28‑$1.48. The earnings beat lifted the non‑GAAP operating margin to 19.9%, up 147 bps YoY.

A cornerstone of the recent rally is NVIDIA’s $2 billion equity investment and multiyear purchase commitment for Coherent’s advanced laser and optical‑networking products. Management highlighted the partnership as a “long‑term catalyst” for CPO and NPO solutions across AI‑driven workloads.

Regulatory and Clinical Headwinds Hit FICO and Alnylam

Shares of Fair Isaac Corporation (NASDAQ: FICO) have tumbled over the past week, as a sweeping regulatory change by the Federal Housing Finance Agency threatens the company’s lucrative dominance in U.S. mortgage credit scoring. The development has prompted a sharp reappraisal of FICO’s growth prospects and margin sustainability, with the stock trading near 18‑month lows despite record quarterly results and an upgraded full‑year outlook.

Key Figures

5-day share price move

-18.7%

Q3 FY26 revenue

$674.2m

Q3 GAAP net income

$237.2m

FY26 revenue guidance

$2.53bn

The FHFA’s decision allows all U.S. mortgage lenders to use VantageScore—FICO’s lower‑cost rival—for originations sold to Fannie Mae and Freddie Mac. The move undercuts FICO’s near‑exclusive position in the government‑sponsored enterprise (GSE) mortgage market, a segment that accounted for the majority of the company’s recent Scores revenue growth.

Regulatory Action Triggers Market Reassessment

VantageScore, previously limited to a pilot program with 50 lenders, is now available to all lenders, threatening FICO’s share and ability to command premium pricing—historically as much as $10 per score compared with under $1 for VantageScore.

Financial Results and Guidance Raise the Stakes

For the third fiscal quarter ended June 30, FICO reported revenue of $674.2 million, up 26% YoY, with GAAP net income of $237.2 million and GAAP EPS of $10.45, up 41%. The Scores segment generated $458.9 million in revenue, rising 41% as mortgage origination volumes grew 97% in the period. Management raised full‑year guidance to $2.53 billion in revenue and $36.86 in GAAP EPS, but the results missed the most bullish analyst estimates by about 1.5% on revenue.

Alnylam Pharmaceuticals (NASDAQ: ALNY) posted a five‑day loss of 14.2%, wiping roughly $4.8 billion from its market value, as investors reassessed the company’s near‑term growth outlook following a Q2 earnings miss and a regulatory setback.

Q2 Earnings Miss and Guidance Cut

The July 30 8‑K reported revenue of $1.29 billion, but earnings per share of $1.84 fell short of the consensus estimate of $2.00. In the same filing, Alnylam trimmed its 2026 TTR product revenue guidance to a range of $4.4 billion–$4.7 billion, down from the prior $4.9 billion–$5.3 billion outlook.

Regulatory Setback on Onpattro

The company also received a FDA Complete Response Letter for a supplemental NDA seeking an expanded ATTR‑CM label for patisiran (Onpattro). The FDA cited insufficient evidence of clinical meaningfulness, overturning an earlier advisory committee vote. The CRL removed a near‑term catalyst that had been priced into the stock.

Underlying Themes and Outlook

The five‑day winners are tied to sectors benefiting from macro‑driven demand: Petrobras from higher oil prices and a favourable political environment, and Lumentum/Coherent from the accelerating rollout of AI‑driven data‑center infrastructure and long‑term supply contracts with Nvidia. Their earnings and guidance provide concrete cash‑flow visibility, which has prompted investors to price in higher valuations despite elevated multiples.

Conversely, the underperformers are exposed to regulatory risk. FICO’s monopoly on GSE mortgage scoring is being dismantled by the FHFA, directly threatening a high‑margin revenue stream. Alnylam’s setback stems from a regulatory decision that removed a near‑term label expansion, compounding an earnings miss that already pressured a forward P/E of roughly 73.8×, well above the biotech sector average.

Investors appear to be rotating capital toward companies with tangible near‑term cash generation and away from those where future earnings depend on regulatory approvals or policy changes. The continuation of these moves will hinge on whether AI‑related demand sustains its pace, whether oil prices remain above breakeven levels for Petrobras, and whether the FHFA or FDA introduce further policy shifts that could deepen the challenges for FICO and Alnylam.